From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA

Business by 2Firsts
Jan.16.2025
From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA
Heno Bio—a prominent nicotine enterprise—has partnered with leading new tobacco media and think tank 2Firsts to develop a pioneering roadmap for Premarket Tobacco Product Applications (PMTAs) under the U.S. Food and Drug Administration (FDA). This partnership not only sets a precedent for the entire industry to explore new approaches to compliance, but also underscores Heno Bio’s leadership and responsibility as the “starting point” in the new tobacco supply chain.

The “Starting Point” Enterprise: A Game-Changer in Global New Tobacco

 

Nicotine, the core raw material in next-generation products (NGPs), is commonly regarded as the supply chain’s “starting point.” Hubei Heno Biological Engineering Co., Ltd. (hereafter “Heno Bio”) holds this pivotal position through its research, development, and production of nicotine, exerting far-reaching influence across the global NGP landscape.

 

On January 9, 2025, at the 2025 NGP Global Compliance Development New Year Symposium hosted by 2Firsts, Heno Bio and 2Firsts officially announced a strategic alliance focused on compliance—instantly capturing industry-wide attention. The event’s theme, “Compliance Drives Growth,” resonates with the sector’s urgent demand for solid regulatory foundations as NGPs continue to evolve rapidly.

 

Two key messages emerged from the Symposium:

 

1. 2025 as the Starting Point: The future trajectory of the industry will hinge on robust compliance measures.

 

2. Supply Chain Empowerment: By initiating strategic action at the “starting point” of the value chain, Heno Bio aims to cascade compliance benefits across downstream stakeholders.

 

From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA
Liu Qizhou (right) and Echo Guo (left) sign the strategic cooperation agreement on behalf of Heno Bio and 2Firsts. Image courtesy of 2Firsts.

 

This partnership not only enhances Heno Bio’s commitment to regulatory standards but also leverages 2Firsts’ role as a leading global media and think tank in the NGP space, amplifying best practices and insights to a worldwide audience.

 

The World’s First Nicotine Enterprise to Publicly Announce a PMTA-TPMF Application

 

During the Symposium’s strategic partnership ceremony, Heno Bio General Manager Liu Qizhou delivered a keynote titled “Compliance Best Practices from a Nicotine Enterprise Perspective.”

 

从“原点”推动全产业链合规进程——和诺生物与2Firsts战略联手打造新型烟草供应链PMTA合规先行者范本
Liu Qizhou speaks on Heno Bio’s compliance journey at the 2025 NGP Global Compliance Development New Year Symposium. Image courtesy of 2Firsts.

 

Liu highlighted that Heno Bio was among the first batch of companies in China to secure a Tobacco Monopoly Production Enterprise License in 2022 and successfully renewed it in 2023—reflecting the firm’s longstanding dedication to regulatory adherence. Now, by publicly announcing its PMTA application in the United States, Heno Bio stands out as the world’s first nicotine enterprise to openly take this critical step, reinforcing its image as a forward-looking force in global NGP compliance.

 

从“原点”推动全产业链合规进程——和诺生物与2Firsts战略联手打造新型烟草供应链PMTA合规先行者范本
A slide from Mr. Liu Qizhou’s presentation illustrating Heno Bio’s role as a compliance leader.

 

According to 2Firsts COO Echo Guo, Heno Bio’s pioneering stance not only elevates the company’s global competitiveness but also offers valuable compliance solutions to downstream players. It serves as a real-world example of how a supply-chain leader can champion new regulatory ideas and frameworks.

 

Why PMTA Is the Global “Entry Ticket”

 

Heno Bio’s compliance strategy centers on obtaining PMTA approval in the United States—the world’s largest e-cigarette market, holding roughly one-third of global market share. Beyond its market size, the U.S. also shapes international trends in both product innovation and regulatory direction. The FDA’s PMTA (Premarket Tobacco Product Applications) system is known for its rigorous and science-based criteria, often dubbed the “gold standard” of the industry.

 

Since the FDA formalized its PMTA framework in 2021, 34 products have received Marketing Granted Orders (MGOs), primarily from major multinational tobacco corporations. Looking ahead, 2024 marks the opening phase of the FDA’s “5-Year Strategic Plan,” which merges accelerated reviews with more stringent enforcement. By 2025, most e-cigarette and NGP brands seeking entry into the U.S. market will likely face PMTA requirements as a non-negotiable step.

 

“TPMF + TPMP”: A Two-Pronged Compliance Approach

 

Although Full PMTA applications are typically filed by brand owners or manufacturers, Heno Bio—positioned at the “starting point” of the supply chain—has proactively pursued compliance through the FDA’s TPMF (Tobacco Product Master Files) and TPMP (Requirements for Tobacco Product Manufacturing Practice).

 

1. Proactive Self-Regulation
By documenting its processes and adhering to rigorous production standards, Heno Bio demonstrates its scientific and technological strengths in meeting regulatory benchmarks.

 

2. Downstream Enablement
Once Heno Bio’s nicotine-related master files are approved, downstream brands can reference Heno Bio’s TPMF in their own PMTA submissions (with authorization), eliminating redundant testing and paperwork. This can significantly reduce both compliance costs and time-to-market.

 

Building a Supply Chain Blueprint for PMTA

 

How the “Starting Point” Accelerates the Entire Value Chain

 

As the global new tobacco market continues to expand and regulations tighten, every sector node—from research and development to sales—must integrate compliance measures. The Heno Bio–2Firsts alliance underscores the strategic advantage of initiating compliance at the “starting point,” ultimately benefiting the entire supply chain.

 

Heno Bio’s fortification of regulatory standards signals a call to action for its upstream suppliers to ensure legal, safe, and high-quality raw material sourcing. This move further reassures downstream stakeholders, offering greater confidence in product safety and regulatory clarity. Such an impact has the potential to transform the market, paving the way for a more stable and sustainable future for NGPs worldwide.

 


 

About HENO

 

Hubei Heno Biological Engineering Co., Ltd. is one of the first batch of natural nicotine production enterprises in the country to obtain the "Tobacco Monopoly Production Enterprise License", and the first domestic enterprise to apply for the raw material production permit with the natural nicotine extraction process route. It has obtained the "Drug Production License" issued by the Hubei Provincial Drug Administration, is a national-level specialized, refined, unique and innovative giant enterprise, a nicotine production enterprise with CANS laboratory nicotine testing capabilities, and a customs advanced certification (AEO) enterprise. The company has drafted the "Production, Processing and Technical Control Specifications for (1-Methyl-2-(3-pyridyl)pyrrolidine)", filling the global standard gap in the production, processing and technical control of natural nicotine. The company has built a safe, environmentally friendly, green and 5G smart park in Baiyangping Industrial Park Chemical Zone in Enshi, Hubei, with an annual capacity to process more than 60,000 tons of tobacco waste and a nicotine production capacity of more than 600 tons.
 

Company's official website:https://www.henonicotine.com/about-us_d1

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
German prosecutors and customs authorities are conducting a criminal investigation into an alleged cross-border organised vape network. Authorities say that between January 2024 and March 2025, four employees of an unnamed Chinese e-cigarette manufacturer allegedly built a network of sales agents and wholesalers that brought more than 7.6 million nicotine disposable vapes into Germany, causing an estimated €33.3 million in excise-tax losses. The manufacturer has not been named. Some products visible in enforcement images have packaging resembling products from FUMOT’s portfolio. European regulatory records from 2024, FUMOT’s public overseas-sales materials and records involving German vape importer and distribution company Zamu-Pro GmbH also show FUMOT/RandM products and German distribution activity during the period covered by the investigation.
Sep.21
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03